key: cord-0823193-252cdv7d authors: Vitiello, A.; Ferrara, F.; Troiano, V.; La Porta, R. title: COVID-19 vaccines and decreased transmission of SARS-CoV-2 date: 2021-07-19 journal: Inflammopharmacology DOI: 10.1007/s10787-021-00847-2 sha: bfe720d25377d7aac18b9820e627f0116c72c2d2 doc_id: 823193 cord_uid: 252cdv7d A massive COVID-19 vaccination campaign is underway worldwide. Epidemiological data from studies indicate excellent efficacy and safety profile for COVID-19 vaccines. However, there are few data from studies on the effect of decreasing the probability of infection of vaccinated subjects compared to unvaccinated subjects. In this short communication, we describe some evidence on this important and current topic providing useful personal reflections. The global COVID-19 pandemic is currently underway (Khan et al. 2020) . Pharmacological treatments for the treatment of COVID-19 infection are mostly directed at avoiding severe complications of the disease Ferrara and Vitiello 2021a) . To date, there are no antivirals directed against SARS-CoV-2, good efficacy has been demonstrated for some antivirals, authorized for other infectious diseases, such as Remdesivir (Vitiello et al. 1971; Vitiello and Ferrara 2020; Ferrara et al. 2020; Ferrara and Vitiello 2021b) . Since December 2020, a massive vaccination campaign has begun worldwide. The vaccines in use, using different methods, mRNA, viral vector, to date the clinical evidence in the epidemiological data post-authorization show excellent efficacy and safety profile Polack et al. 2020; Knoll and Wonodi 2021) . However, probably what has been poorly studied in the phase 3 pre-registration studies and in the post-authorization clinical trials, is whether the vaccinated subject infects with the same frequency and probability as an unvaccinated subject, and, if the vaccinated subject can be equally contagious as an unvaccinated and COVID-19-positive subject. Pre-registration phase 3 clinical trials, as is traditional for vaccines, evaluate therapeutic efficacy by investigating the vaccinated subject's protection from the disease. Even for COVID-19 vaccines, preregistrative phase 3 studies have evaluated the protection of subjects from disease, albeit with different results among vaccines (Lurie et al. 2020; Voysey et al. 2021) . However, it is certain that protection from severe disease by vaccines is of enormous importance, but probably of equal importance is understanding whether vaccination also decreases virus transmission and the number of people infected (Wiersinga et al. 2020 ). These goals are made even more important given the current lack of antiviral drugs directed against SARS-CoV-2 . Several vaccines against COVID-19 are currently licensed, using different modes of action. Epidemiological data also show different efficacy, which may also indirectly influence the ability to decrease virus transmission. The BioNTech/ Pfizer BNT162b2 mRNA method vaccine conferred 95% protection against COVID-19 in persons 16 years of age or older (Polack et al. 2020 Recent evidence shows a decrease in contagiousness among vaccinated people. In a study carried out in Israel, the viral load present in the nasal mucosa of a sample of healthcare workers was evaluated on a weekly basis. The conclusion of the study showed that in vaccinated and COVID-19-positive persons, the viral load was 2-4 times lower than in unvaccinated persons (Callaway 2021 The scientific interpretation of the results of these clinical studies clearly demonstrates the correlation between the decrease in SARS-CoV-2 viral load and probability of infection, and vaccinated subjects. The molecular hypothesis underlying these results, suggest that in the vaccinated subject and COVID-19 positive may be present the virus, structurally intact, but immediately covered with antibodies of the subject, which make the virus unable to infect other people. Probably this may also be related to the fact that asymptomatic COVID-19-positive individuals are less contagious than individuals with severe infection, precisely because in asymptomatic individuals the immune system has an excellent response, immediately attacking the virus, slowing its replication and decreasing its potency and the likelihood of infecting other people (Petter et al. 2021; Thompson et al. 2021; Wang et al. 2020; Yu and Yang 2020; Huff and Singh 2020) . This hypothesis is further reinforced by the evidence showing that people with lower viral load in circulation transmit are less contagious, further suggesting that asymptomatic infections are less likely to infect other individuals. However, it would be essential to be able to vaccinate the largest number of the world's population in a short time, avoiding huge differences between the countries. Current clinical evidence shows that COVID-19 vaccination protects against severe symptoms of the disease but is also an important tool to decrease the spread of the virus and the rate of infection. At this point in time, the global COVID-19 pandemic is complex, some countries have vaccinated a large portion of their population, others have difficulty accessing vaccination, and there is a wide variety of measures put in place and closures between the countries. These discrepancies may bring out variants of the virus, and prolong the global pandemic phase. Vaccinated individuals are likely to be less likely to transmit the virus; however, it remains critical to continue to maintain responsible behaviors. Author contributions All the authors contributed equally to the manuscript and had the opportunity to revise and approve the final text. Funding None. Data availability No availability of supporting data. Ethical approval Not applicable. Consent to participate Not applicable. Delta coronavirus variant: scientists brace for impact Scientific hypothesis for treatment of COVID-19's lung lesions by adjusting ACE/ACE2 imbalance COVID-19 vaccines and decreased transmission of SARS-CoV-2 Efficacy of synthetic glucocorticoids in COVID-19 endothelites Remdesivir and COVID-19 Asymptomatic transmission during the coronavirus disease 2019 pandemic and implications for public health strategies COVID-19: a global challenge with old history, epidemiology and progress so far Oxford-AstraZeneca COVID-19 vaccine efficacy SARS-CoV-2 variants and vaccines Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine Developing Covid-19 vaccines at pandemic speed Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2 C4591001 Clinical Trial Group (2020) Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers-eight Remdesivir versus ritonavir/lopinavir in COVID-19 patients Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19 Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients Colchicine and SARS-CoV-2: management of the hyperinflammatory state Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade Drugs acting on the reninangiotensin system and SARS-CoV-2 Oxford COVID Vaccine Trial Group (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Decoding asymptomatic COVID-19 infection and transmission Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review COVID19 transmission through asymptomatic carriers is a challenge to containment Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations